Evidenceforanassociationofserummicroanalytesandmyofascialpainsyndrome

Myofascial Pain Syndrome (MPS) affects about 15% of people seeking medical attention in the US, but diagnosing it remains challenging because clinicians disagree on the criteria. While doctors typically look for trigger points (tender spots in muscles) and other physical signs, these findings can be unreliable and subjective. The lack of precise diagnostic tools makes it difficult to select effective treatments and understand what causes MPS. This study aimed to discover whether specific substances in the blood (called microanalytes) might correlate with the physical findings commonly seen in MPS patients, potentially providing a more objective way to diagnose and understand the condition.

Researchers recruited 38 people (25 women, average age 32) who had experienced myofascial pain in their upper trapezius (shoulder/neck area) for at least three months. All participants underwent comprehensive physical examinations by experienced clinicians who checked for trigger points, measured range of motion in the shoulders and neck, tested muscle strength, and assessed joint flexibility using the Beighton Index. They also measured pain sensitivity using a pressure device and collected self-reported pain scores. Most importantly, each participant provided a fasting blood sample that was analyzed for 21 different substances, including inflammatory markers (cytokines), growth factors, and brain chemicals (neurotransmitters).

The researchers then used statistical analysis to look for correlations between these blood markers and the clinical findings.

The study revealed several significant correlations between blood markers and clinical measurements. People with more joint flexibility (higher Beighton scores) had higher levels of certain inflammatory markers, particularly IL-5 and IL-7, along with growth factors GM-CSF and DHEA. Those with asymmetrical movement patterns - where one side of the body moved differently than the other - showed associations with various cytokines. The researchers found that several inflammatory markers clustered together, suggesting they work as a group.

Additionally, brain-derived factors like BDNF correlated with other neurochemicals including NPY and acetylcholine. About 21% of participants had widespread pain, and 35% showed hypermobility. The most common trigger point locations were in the upper trapezius region, with active trigger points showing lower pain thresholds than latent ones.

This research provides the first evidence that specific blood markers might be linked to the physical findings commonly seen in people with myofascial pain syndrome. While this is preliminary research with a small group, it suggests that MPS involves measurable biochemical changes that could potentially be used for diagnosis in the future. The correlation between joint flexibility and certain inflammatory markers is particularly interesting because it suggests a biological basis for why some people with connective tissue differences might be more prone to developing MPS. For patients, this research represents a step toward more precise diagnosis and potentially personalized treatments.

For clinicians, it offers hope for objective biomarkers that could complement physical examination findings, leading to more consistent diagnosis and better treatment selection. However, more research with larger groups is needed to confirm these findings and determine if blood tests could become a practical diagnostic tool.